4D Molecular Therapeutics, Inc. — Director's Dealing 2021

Mar 10, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: 4D Molecular Therapeutics Inc. (FDMT)
CIK: 0001650648
Period of Report: 2021-03-08

Reporting Person: Kirn David (Director, See Remarks, 10% Owner)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-08	Stock Option (Right to Buy)	$41.66	A	150000	Acquired	2031-03-07	Common Stock (150000)	Direct

Footnotes

F1: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 8, 2021 (the "Vesting Commencement Date") while the grantee remains a service provider to the Company.